Clinical Trial Update: A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

This completed Phase 2 trial evaluated the combination of Zevalin with BEAM high-dose chemotherapy followed by autologous stem cell transplantation in patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Conditions: Primary Non-Hodgkin-Lymphoma, Refractory Non-Hodgkin-Lymphoma | Phase 2 | Status: COMPLETED